Ratings by B.Riley (Madhu Kumar)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/25/2021 Dicerna Pharmaceuticals DRNA Maintain Buy
(N/A)
 
 
  Details
1/11/2021 Dicerna Pharmaceuticals DRNA Maintain Buy
(N/A)
 
 
  Details
11/13/2019 Arrowhead Research ARWR Maintain Buy
(N/A)
 
 
  Details
10/7/2019 Arbutus Biopharma ABUS Maintain Buy
(N/A)
 
 
  Details
8/19/2019 Arrowhead Research ARWR Maintain Buy
(N/A)
 
 
  Details
5/28/2019 Arrowhead Research ARWR Maintain Buy
(N/A)
 
 
  Details
3/12/2019 Dicerna Pharmaceuticals DRNA Maintain Buy
(N/A)
 
 
  Details
11/15/2018 uniQure BV QURE Maintain Buy
(N/A)
 
 
  Details
11/7/2018 Spark Therapeutics ONCE Upgrade Buy
(Neutral)
44.02
(110.05)
150% Details
11/7/2018 Audentes Therapeutics BOLD Maintain Sell
(N/A)
 
 
  Details
11/6/2018 Dicerna Pharmaceuticals DRNA Upgrade Buy
(Neutral)
13.49
(21.83)
61.82% Details
10/22/2018 Deciphera DCPH Maintain Neutral
(N/A)
 
 
  Details
10/16/2018 Arbutus Biopharma ABUS Upgrade Buy
(Neutral)
4.31
(4.03)
-6.5% Details
10/8/2018 Assembly Biosciences ASMB Upgrade Buy
(Neutral)
27.93
(3.13)
-88.79% Details
9/26/2018 TG Therapeutics TGTX Maintain Buy
(N/A)
 
 
  Details
9/20/2018 Tocagen Inc. TOCA Maintain Buy
(N/A)
 
 
  Details
9/13/2018 Apellis Pharmaceuticals APLS Maintain Buy
(N/A)
 
 
  Details
9/7/2018 Homology Medicines FIXX New Coverage Neutral
(N/A)
17.06
(6.00)
-64.83% Details
9/7/2018 ChemoCentryx CCXI New Coverage Neutral
(N/A)
12.61
(11.83)
-6.19% Details
9/7/2018 Zogenix, Inc. ZGNX New Coverage Buy
(N/A)
48.65
(15.54)
-68.06% Details
9/7/2018 Audentes Therapeutics BOLD New Coverage Sell
(N/A)
37.57
(59.97)
59.62% Details
9/6/2018 Arrowhead Research ARWR Upgrade Buy
(Neutral)
14.10
(66.03)
368.3% Details
8/24/2018 Immunomedics IMMU Maintain Buy
(N/A)
 
 
  Details
8/15/2018 Clementia Pharmaceuticals Inc. CMTA Maintain Buy
(N/A)
 
 
  Details
8/14/2018 Regulus Therapeutics RGLS Maintain Neutral
(N/A)
 
 
  Details
8/14/2018 Eiger BioPharma EIGR Maintain Buy
(N/A)
 
 
  Details
8/13/2018 Arbutus Biopharma ABUS Maintain Neutral
(N/A)
 
 
  Details
8/13/2018 Alnylam Pharmaceuticals ALNY Maintain Buy
(N/A)
 
 
  Details